Tirzepatide

What it is

GIP and GLP-1 are both incretin hormones, natural signals the gut releases after a meal that help the body manage blood sugar and appetite. Most earlier weight and diabetes medicines in this class act on the GLP-1 receptor alone. Tirzepatide is built to activate both receptors together, which researchers describe as its defining feature compared with single-target medicines.

That dual action is proposed to work through several channels at once: prompting the body to release insulin in a way that depends on current blood sugar levels, slowing how quickly the stomach empties, and reducing appetite signals in the brain. Clinical trials comparing tirzepatide with GLP-1-only medicines have generally reported larger effects on both body weight and blood sugar control, though the two mechanisms have not been separated out to show exactly how much each receptor contributes on its own.

How it is studied

Tirzepatide's human trial program is large by the standards of newly developed peptides. It includes placebo-controlled trials in adults with obesity, a separate program for people who have type 2 diabetes, and a multi-year outcomes trial tracking heart-related events in thousands of participants with diabetes. Trials have generally run from about 18 months to several years, considerably longer than the trial periods typical of earlier-stage investigational compounds, giving tirzepatide one of the more mature human evidence bases among the peptides in this reference.

What studies report

• In a 72-week trial enrolling adults who had both type 2 diabetes and obesity, the highest tested amount of tirzepatide was linked to an average weight reduction of 15.7 percent alongside improvement across several cardiometabolic measures. [1]
• In a separate 72-week trial of adults with obesity but not diabetes, the highest tested amount of tirzepatide was linked to an average weight reduction of 22.5 percent, compared with 2.4 percent on placebo, among the largest reductions reported in a pharmaceutical weight-management trial. [2]
• In a trial enrolling adults who had both type 2 diabetes and obesity, weight reduction on tirzepatide came with measurable improvements in blood pressure, triglycerides, and other markers linked to cardiovascular risk. [1]

What is not known

Because tirzepatide is relatively new, there is no multi-decade safety record comparable to older diabetes medicines, and long-term questions about weight regain after stopping treatment, effects with many years of continuous use, and outcomes in populations not well represented in the trials, such as adolescents or people with several coexisting conditions, remain areas of ongoing research rather than settled findings.

Reported adverse findings

• Across the trial program, gastrointestinal reactions such as nausea were the most commonly reported side effect, and regulators have flagged a contraindication in people who have themselves had, or have a close relative who has had, a rare thyroid cancer. [1]

Regulatory status

Tirzepatide is approved by the United States Food and Drug Administration under the brand name Mounjaro for type 2 diabetes and under the brand name Zepbound for chronic weight management. It is a prescription-only medicine in the United States and Canada and is not available without a prescription in either country.